keyword
MENU ▼
Read by QxMD icon Read
search

DMARDs

keyword
https://www.readbyqxmd.com/read/28217907/diet-and-rheumatoid-arthritis-symptoms-survey-results-from-a-rheumatoid-arthritis-registry
#1
Sara K Tedeschi, Michelle Frits, Jing Cui, Zhi Zack Zhang, Taysir Mahmoud, Christine Iannaccone, Tzu-Chieh Lin, Kazuki Yoshida, Michael E Weinblatt, Nancy A Shadick, Daniel H Solomon
OBJECTIVE: Patients with RA often ask if specific foods, popularized as "inflammatory" or "anti-inflammatory," can improve or worsen their RA. We surveyed patients regarding diet and RA symptoms. METHODS: We mailed a diet survey to 300 subjects in a single-center RA registry at a large academic center. Subjects were asked whether they consume each of 20 foods and whether these foods make their RA symptoms better, worse, or unchanged. Semi-annual registry data include demographics, medications, comorbidities, and disease activity scores...
February 19, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28217885/reductions-in-radiographic-progression-in-early-ra-over-25-years-changing-contribution-from-rf-in-2-multi-centre-uk-inception-cohorts
#2
Lewis Carpenter, Sam Norton, Elena Nikiphorou, Keeranur Jayakumar, Daniel F McWilliams, Kirsten L Rennie, Josh Dixey, Patrick Kiely, David Andrew Walsh, Adam Young
OBJECTIVES: To assess 5-year progression of erosions and Joint Space Narrowing (JSN), and their associations with RF status in two large, multi-centre early-RA cohorts spanning 25-years. METHODS: Radiographic joint damage was recorded using the Sharp/van der Heijde (SvdH) method in the Early RA Study (ERAS) 1986-2001, and the Early RA Network (ERAN) 2002-2013. Mixed-effects negative-binomial regression estimated changes in radiographic damage over 5-years, including erosions and JSN separately...
February 19, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28216195/golimumab-in-real-life-settings-2-years-drug-survival-and-predictors-of-clinical-outcomes-in-rheumatoid-arthritis-spondyloarthritis-and-psoriatic-arthritis
#3
Florenzo Iannone, Leonardo Santo, Maria Grazia Anelli, Romano Bucci, Angelo Semeraro, Laura Quarta, Francesca D'Onofrio, Antonio Marsico, Giorgio Carlino, Oriana Casilli, Fabio Cacciapaglia, Carmelo Zuccaro, Paola Chiara Falappone, Francesco Paolo Cantatore, Maurizio Muratore, Giovanni Lapadula
OBJECTIVES: To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS: This is a non-interventional, longitudinal study on RA, SpA, and PsA patients starting treatment with golimumab. Endpoints were the 2 years persistence rate of golimumab and predictors of therapy discontinuation. Drug retention was analyzed using Kaplan-Meier and Cox models...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28216194/safety-of-resuming-biologic-dmards-in-patients-who-develop-tuberculosis-after-anti-tnf-treatment
#4
Soo-Kyung Cho, Dam Kim, Soyoung Won, Minkyung Han, Jiyoung Lee, Eun Jin Jang, Tae-Hyung Kim, Sang-Cheol Bae, Yoon-Kyoung Sung
OBJECTIVES: To estimate the incidence of tuberculosis (TB) in rheumatoid arthritis (RA) patients treated with tumor necrotizing factor inhibitor (TNFI) and evaluate the safety of resuming biologic disease-modifying anti-rheumatic drugs (DMARDs) in patients who developed TB after anti-TNF treatment. METHODS: We conducted an inception cohort study of RA patients in the Korean Healthcare Claims Database who started TNFI as the first biologic DMARD between January 2009 and December 2013...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28215362/efficacy-and-safety-of-sirukumab-in-patients-with-active-rheumatoid-arthritis-refractory-to-anti-tnf-therapy-sirround-t-a-randomised-double-blind-placebo-controlled-parallel-group-multinational-phase-3-study
#5
Daniel Aletaha, Clifton O Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul P Tak, Sharon Popik
BACKGROUND: Sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, is under development for the treatment of rheumatoid arthritis and other diseases. We aimed to assess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T). METHODS: We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre study at 183 hospitals and private rheumatology clinics in 20 countries (Argentina, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Taiwan, UK, and USA)...
February 15, 2017: Lancet
https://www.readbyqxmd.com/read/28214924/characteristics-and-outcomes-of-rheumatoid-arthritis-patients-who-started-biosimilar-infliximab
#6
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Soyoung Won, Chan-Bum Choi, So-Young Bang, Seung-Jae Hong, Hyoun Ah Kim, Eun-Mi Koh, Hye-Soon Lee, Chang-Hee Suh, Dae-Hyun Yoo, Sang-Cheol Bae
To compare the characteristics of rheumatoid arthritis (RA) patients receiving either biosimilar or originator infliximab and to identify the effectiveness and safety of biosimilar infliximab in RA patients in real-world practice. RA patients who started either biosimilar or originator infliximab were selected using the prospective biologic disease-modifying anti-rheumatic drugs (DMARDs) registry: BIOlogics Pharmacoepidemiologic StudY (BIOPSY). Baseline characteristics of the two groups were compared, and short-term treatment outcomes, including DAS28-ESR and HAQ-DI scores, were compared after initiation of biosimilar or originator infliximab...
February 18, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28213862/apremilast-a-review-in-psoriasis-and-psoriatic-arthritis
#7
Gillian M Keating
Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast...
February 18, 2017: Drugs
https://www.readbyqxmd.com/read/28202919/ectopic-lymphoid-neogenesis-in-rheumatic-autoimmune-diseases
#8
REVIEW
Michele Bombardieri, Myles Lewis, Costantino Pitzalis
Ectopic lymphoid neogenesis often occurs in the target tissues of patients with chronic rheumatic autoimmune diseases such as rheumatoid arthritis, Sjögren syndrome and other connective tissue disorders, including systemic lupus erythematosus and myositis. However, the mechanisms of ectopic lymphoid-like structure (ELS) formation and function are not entirely understood. For example, it is unclear whether ELSs indicate distinct disease phenotypes or whether they are evolutionary manifestations of chronic inflammation...
March 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28194545/to-stop-the-erosion-of-hope-the-dmard-category-and-the-place-of-semantics-in-modern-rheumatology
#9
Jonas Kure Buer
The category of disease-modifying anti-rheumatic drugs (DMARDs) emerged in the 1970s to describe drugs capable of altering the long-term destructive course of arthritis. It became a core concept in rheumatology's reorientation towards pharmaceuticals in the late twentieth century. By examining the earliest use of the term "disease-modifying" in scientific publications, this paper identifies the drugs that the category described when it first emerged. Leaning on systematic reviews of each of these drugs towards the end of their career in rheumatology, it then establishes that posterity would not recognize any of these early DMARDs as capable of altering the long-term course of the disease...
February 13, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/28176966/efficacy-and-safety-of-non-pharmacological-and-non-biological-pharmacological-treatment-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#10
COMMENT
Andrea Regel, Alexandre Sepriano, Xenofon Baraliakos, Désirée van der Heijde, Jürgen Braun, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthritis (axSpA) to inform the update of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of axSpA. A systematic literature review (2009-2016) of all non-pharmacological treatments, non-biological drugs (except targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) and surgical therapies was performed. Randomised controlled trials (RCTs) and clinical controlled trials were assessed for efficacy and safety, while observational studies with a comparator were assessed for safety...
2017: RMD Open
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#11
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28166785/a-comparison-of-three-treatment-strategies-in-recent-onset-non-systemic-juvenile-idiopathic-arthritis-initial-3-months-results-of-the-best-for-kids-study
#12
P C E Hissink Muller, D M C Brinkman, D Schonenberg, Y Koopman-Keemink, I C J Brederije, W P Bekkering, T W Kuijpers, M A J van Rossum, L W A van Suijlekom-Smit, J M van den Berg, C F Allaart, R Ten Cate
BACKGROUND: Combination therapy with prednisone or etanercept may induce earlier and/or more improvement in disease activity in Disease Modifying Anti Rheumatic Drug (DMARD) naïve non-systemic Juvenile Idiopathic Arthritis (JIA) patients. Here we present three months clinical outcome of initial treatments of the BeSt-for-Kids study. METHODS: Included patients were randomized to either: 1. initial DMARD-monotherapy (sulfasalazine (SSZ) or methotrexate (MTX)), 2...
February 6, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28161984/formulation-of-piperine-solid-lipid-nanoparticles-sln-for-treatment-of-rheumatoid-arthritis
#13
M R Bhalekar, A R Madgulkar, Puja S Desale, Gyce Marium
The purpose of this work was to formulate piperine solid lipid nanoparticle (SLN) dispersion to exploit its efficacy orally and topically. Piperine-SLN were prepared by melt emulsification method and formula was optimized by the application of 3(2) factorial design. The nanoparticulate dispersion was evaluated for particle size, entrapment efficiency (EE) and zeta potential(ZP). Optimized batch (128.80 nm average size, 78.71% EE and -23.34 Mv Zeta Potential) was characterized for differential scanning calorimetry (DSC), X-ray diffraction(XRD) which revealed amorphous nature of piperine in SLN...
February 6, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/28160071/adherence-to-combination-dmard-therapy-and-treatment-outcomes-in-rheumatoid-arthritis-a-longitudinal-study-of-new-and-existing-dmard-users
#14
Nasir Wabe, Anita Lee, Mihir Wechalekar, Leah McWilliams, Susanna Proudman, Michael Wiese
Medication adherence is believed to be a major contributor to treatment outcomes yet studies quantifying this relationship as rare in rheumatoid arthritis (RA). To determine the association of adherence to DMARD therapy with treatment outcomes among new and existing DMARD users over 2 years. Relevant clinical parameters were obtained from a longitudinal cohort of RA patients, most of who were treated with combination therapy. Patients were classified as adherent if the proportion of days covered for each DMARD was ≥80%...
February 3, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28152001/does-non-adherence-to-dmards-influence-hospital-related-healthcare-costs-for-early-arthritis-in-the-first-year-of-treatment
#15
Annelieke Pasma, Charlotte Schenk, Reinier Timman, Adriaan van 't Spijker, Cathelijne Appels, Willemijn H van der Laan, Bart van den Bemt, Robert Goekoop, Johanna M W Hazes, Jan J V Busschbach
INTRODUCTION: Non-adherence to disease-modifying antirheumatic drugs (DMARDs) is suspected to relate to health care costs. In this study we investigated this relation in the first year of treatment. METHODS: In a multi-center cohort study with a one year follow up, non-adherence was continuously measured using electronic monitored medication jars. Non-adherence was defined as the number of days with a negative difference between expected and observed opening of the container...
2017: PloS One
https://www.readbyqxmd.com/read/28151971/eq-5d-utility-response-and-drug-survival-in-rheumatoid-arthritis-patients-on-biologic-monotherapy-a-prospective-observational-study-of-patients-registered-in-the-south-swedish-ssatg-registry
#16
Tanja Schjødt Jørgensen, Carl Turesson, Meliha Kapetanovic, Martin Englund, Aleksandra Turkiewicz, Robin Christensen, Henning Bliddal, Pierre Geborek, Lars Erik Kristensen
OBJECTIVES: Biologic agents have dramatically changed treatment of rheumatoid arthritis (RA). To date only scarce head-to-head data exist especially when the biological therapies are given as monotherapy without concomitant disease modifying drugs (DMARDs). Thus the objective of the current study is to evaluate treatment response of all available biological therapies with special focus on utility (EQ-5D-3L) and drug survival of biologic DMARDs (bDMARDs) prescribed as monotherapy in RA patients in southern Sweden...
2017: PloS One
https://www.readbyqxmd.com/read/28151539/non-pharmacological-and-pharmacological-interventions-in-patients-with-early-arthritis-a-systematic-literature-review-informing-the-2016-update-of-eular-recommendations-for-the-management-of-early-arthritis
#17
Claire Immediato Daien, Charlotte Hua, Bernard Combe, Robert Landewe
OBJECTIVE: To perform a systematic literature review (SLR) on pharmacological and non-pharmacological treatments, in order to inform the European League Against Rheumatism (EULAR) recommendations for the management of early arthritis (EA). METHODS: The expert committee defined research questions concerning non-pharmacological interventions, patient information and education, non-steroidal anti-inflammatory drug, glucocorticoid (GC) and disease-modifying antirheumatic drugs (DMARDs) use, as well as on disease monitoring...
2017: RMD Open
https://www.readbyqxmd.com/read/28149009/serum-lipid-alterations-in-early-rheumatoid-arthritis-patients-on-disease-modifying-anti-rheumatoid-therapy
#18
Sana Parveen, Rachel Jacob, Liza Rajasekhar, C Srinivasa, Iyyapu Krishna Mohan
Dyslipidaemia is a major CVD risk factor in the general population. Current evidence suggests that lipid metabolism is altered in RA due to inflammation, and that use of anti-inflammatory therapy may reverse some of these changes. The objective of our study is to compare the effect of treatment with DMARD on lipid fractions after 6 months of therapy. Forty patients who met the American College of Rheumatology, ACR/EULAR criteria for rheumatoid arthritis, with disease duration of less than 1 year and no prior treatment were included in the study...
March 2017: Indian Journal of Clinical Biochemistry: IJCB
https://www.readbyqxmd.com/read/28148302/blood-chemokine-profile-in-untreated-early-rheumatoid-arthritis-cxcl10-as-a-disease-activity-marker
#19
Jayesh M Pandya, Anna-Carin Lundell, Kerstin Andersson, Inger Nordström, Elke Theander, Anna Rudin
BACKGROUND: We have recently analyzed the profile of T-cell subtypes based on chemokine receptor expression in blood from untreated early rheumatoid arthritis (ueRA) patients compared to healthy controls (HC). Here, we compared the levels of the respective chemokines in blood plasma of ueRA patients with those of HC. We also studied the association of chemokine levels with the proportions of circulating T-cell subsets and the clinical disease activity. METHODS: Peripheral blood was obtained from 43 patients with ueRA satisfying the ACR 2010 criteria and who had not received any disease-modifying anti-rheumatic drugs (DMARD) or prednisolone, and from 14 sex- and age-matched HC...
February 2, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28143836/periodontitis-in-early-and-chronic-rheumatoid-arthritis-a-prospective-follow-up-study-in-finnish-population
#20
Leena Äyräväinen, Marjatta Leirisalo-Repo, Antti Kuuliala, Kirsi Ahola, Riitta Koivuniemi, Jukka H Meurman, Anna Maria Heikkinen
OBJECTIVES: To investigate the association between rheumatoid arthritis (RA) and periodontitis with special emphasis on the role of antirheumatic drugs in periodontal health. DESIGN: Prospective follow-up study. Patients with early untreated RA and chronic active RA were examined at baseline and 16 months later. Controls were examined once. SETTINGS AND PARTICIPANTS: The study was conducted in Finland from September 2005 to May 2014 at the Helsinki University Hospital...
January 31, 2017: BMJ Open
keyword
keyword
86203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"